CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 174 enrolled
Drug / intervention
XEN Group +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03868254
NCT03868254N/ACompleted
CompareCT.gov

XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

Allergan·observational·Posted Mar 11, 2019·Updated Nov 17, 2020

In Brief

An observational study evaluating XEN Group and Phacoemulsification for Glaucoma. Completed, enrolled 174 participants across 1 site.

Detailed Summary

A retrospective, non-interventional, observational, multi-center, chart review study to be conducted in participants who underwent placement of the XEN 45 Gel Stent as a standalone procedure or in combination with phacoemulsification from 1 January 2014 to 1 October 2015.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 11, 2019
Enrollment StartApr 5, 2019
Primary CompletionOct 25, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.3 years ago

Interventions

XEN Groupdevice

Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.

Phacoemulsificationprocedure

Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.